Evaluating circulating tumor cells in lung cancer patients
Detection of Circulating Tumour Cells, Spread Through Air Space and Lymph-nodal Micrometastasis in Patients With Lung Cancer Undergoing Surgical Resection With Curative Intent
IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06833632
This study is trying to see if checking for certain cancer cells in the blood can help doctors identify lung cancer patients who are at higher risk of their cancer coming back after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna (other) |
| Locations | 1 site (Bologna, Emilia-Romagna) |
| Trial ID | NCT06833632 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prognostic significance of circulating tumor cells (CTCs) and lymph node micrometastases in patients with non-small cell lung cancer (NSCLC) undergoing radical surgery. It focuses on understanding the early spread of the disease and identifying high-risk patients for recurrence. By analyzing the presence of CTCs and STAS, the study seeks to provide insights that could influence adjuvant treatment strategies and improve early detection of lung cancer recurrence.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with early-stage non-small cell lung cancer who are eligible for radical surgical resection.
Not a fit: Patients with other active cancers, previous lung cancer surgeries, or those undergoing induction therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk stratification and personalized treatment plans for lung cancer patients, potentially reducing recurrence rates.
How similar studies have performed: While the approach of evaluating circulating tumor cells is gaining traction, this specific study's focus on STAS in NSCLC is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * obtaining voluntary written informed consent * diagnosis of NSCLC * clinical stage I-IIA cN0 * Candidates for surgical resection Exclusion Criteria: * Pregnancy * Induction therapy for pulmonary neoplasia * Patients who have received systemic treatment for previous cancers in the last three years prior to lung surgery * Any previous surgery for lung cancer * Patients with other active neoplasms * Infiltration of the chest wall
Where this trial is running
Bologna, Emilia-Romagna
- IRCCS - Azienda Ospedaliero Universitaria di Bologna — Bologna, Emilia-Romagna, Italy (RECRUITING)
Study contacts
- Principal investigator: Pietro Bertoglio, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Pietro Bertoglio, MD
- Email: pietro.bertoglio@ausl.bologna.it
- Phone: 051 647 8362
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non-Small-Cell Lung Cancer